ArticleJournal of industrial microbiology & biotechnology2019
Sequential improvement of rimocidin production in Streptomyces rimosus M527 by introduction of cumulative drug-resistance mutations.
Article in Journal of industrial microbiology & biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 60 citations in OpenAlex.
- Study on the regulatory mechanism of NsdAMicrobial cell factories · 2025Article
- Transposon-based identification of genes involved in the rimocidin biosynthesis in Streptomyces rimosus M527.World journal of microbiology & biotechnology · 2023Article
- Effects of the Coculture Initiation Method on the Production of Secondary Metabolites in Bioreactor Cocultures ofMolecules (Basel, Switzerland) · 2023Article
- Identification of RimR2 as a positive pathway-specific regulator of rimocidin biosynthesis in Streptomyces rimosus M527.Microbial cell factories · 2023Article
- Improvement of rimocidin production in Streptomyces rimosus M527 by reporter-guided mutation selection.Journal of industrial microbiology & biotechnology · 2023Article
- Identification of Putative Drug Targets in Highly Resistant Gram-Negative Bacteria; and Drug Discovery Against Glycyl-tRNA Synthetase as a New Target.Bioinformatics and biology insights · 2023Article
- Co-cultivation of filamentous microorganisms in the presence of aluminum oxide microparticles.Applied microbiology and biotechnology · 2022Article
- Improvement of Rimocidin Biosynthesis by Increasing Supply of Precursor Malonyl-CoA via Over-expression of Acetyl-CoA Carboxylase in Streptomyces rimosus M527.Current microbiology · 2022Article
- Isolation and Evaluation of Rhizosphere Actinomycetes With Potential Application for BiocontrollingFrontiers in microbiology · 2021Article
- "Microbial Wars" in a Stirred Tank Bioreactor: Investigating the Co-Cultures ofFrontiers in bioengineering and biotechnology · 2021Article
- Identification of a gene from Streptomyces rimosus M527 negatively affecting rimocidin biosynthesis and morphological differentiation.Applied microbiology and biotechnology · 2020Article
- The Antitumor Agent Ansamitocin P-3 Binds to Cell Division Protein FtsZ inBiomolecules · 2020Article
- Engineering the Translational Machinery for Biotechnology Applications.Molecular biotechnology · 2020Review
- Cloning and Overexpression of theFrontiers in microbiology · 2020Article
- The Application of Ribosome Engineering to Natural Product Discovery and Yield Improvement inAntibiotics (Basel, Switzerland) · 2019Review
- Development and optimization of an intergeneric conjugation system and analysis of promoter activity in Streptomyces rimosus M527.Journal of Zhejiang University. Science. BArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rimocidin is a polyene macrolide that exhibits a strong inhibitory activity against a broad range of plant-pathogenic fungi. In this study, fermentation optimization and ribosome engineering technology were employed to enhance rimocidin production in Streptomyces rimosus M527. After the optimization of fermentation, rimocidin production in S. rimosus M527 increased from 0.11 ± 0.01 to 0.23 ± 0.02 g/L during shake-flask experiments and reached 0.41 ± 0.05 g/L using 5-L fermentor. Fermentation optimization was followed by the generation of mutants of S. rimosus M527 through treatment of the strain with different concentrations of gentamycin (Gen) or rifamycin. One Gen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.